Ascendis Pharma A/S Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2025 Revenue: €248 million, including Yorvipath revenue of €187 million and Skytrofa revenue of €53 million.

Full-Year 2025 Revenue: €720 million, with Yorvipath contributing €477 million and Skytrofa €206 million.

Operating Profit: €10 million in Q4; total operating expenses for the year were €761 million.

Operating Cash Flow: €73 million in Q4; €616 million in cash and cash equivalents at year-end, up from €560 million in 2024.

Impact of Currency: Weaker US dollar negatively impacted revenues by approximately €36 million for the year.

2Strategic Updates and Business Highlights

Yorvipath Launch: Strong global launch with over 5,300 patients prescribed by nearly 2,400 healthcare providers in the US. The insurance approval rate is around 70%, with expectations for growth as more patients are initiated on treatment.

Skytrofa Performance: Continued solid performance with a 7% market share in the US. Initiated Phase III trials for additional growth hormone indications.

TransCon PTH: Approved in the US and EU for hypoparathyroidism, with ongoing development for a once-weekly formulation.

Pipeline Expansion: Focus on expanding the label for existing products and developing new therapies, including a collaboration with Novo Nordisk for once-monthly TransCon semaglutide.

3Forward Guidance and Outlook

2026 Expectations: Projected operating cash flow of approximately €500 million and aim for at least €5 billion in annual product revenue by 2030.

Yorvipath Growth: Anticipated continued strong revenue growth in 2026 based on steady patient uptake, with seasonal revenue trends expected.

Skytrofa and TransCon CNP: Expect revenue growth to track prescription increases, with TransCon CNP's US approval anticipated soon.

4Bad News, Challenges, or Points of Concern

Insurance Approval Rate: While the current approval rate for Yorvipath is satisfactory, reaching 100% is unlikely and may take time due to natural filtering of eligible patients.

Competitive Pressures: Concerns regarding emerging competitors like encaleret and long-acting CNP products from BioMarin. Management expressed skepticism about the efficacy of encaleret as a treatment for hypoparathyroidism.

Regulatory Risks: The upcoming PDUFA date for TransCon CNP and the need for ongoing successful regulatory interactions pose inherent risks.

5Notable Q&A Insights

Confidence in TransCon CNP Approval: Management expressed strong confidence in the upcoming approval, reiterating their positive outlook.

Yorvipath Utilization: Broad uptake across prescribers is encouraging, with a mix of patient demographics being treated, primarily post-surgical patients.

Commercial Strategy: Ascendis has built a robust infrastructure for global commercialization, leveraging existing frameworks to expedite the launch of new products.

Long-Term Independence: The CEO emphasized the goal of maintaining independence as a profitable biotech, highlighting the company's financial strength and strategic positioning. Overall, Ascendis Pharma demonstrated strong financial performance in 2025, with a clear strategic vision for growth and product development, despite facing competitive and regulatory challenges.